Market Closed -
Nasdaq
04:00:00 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
50.78
USD
|
-1.09%
|
|
-2.35%
|
-8.50%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,359
|
2,882
|
2,717
|
-
|
-
|
Enterprise Value (EV)
1 |
1,104
|
2,180
|
2,113
|
2,125
|
1,848
|
P/E ratio
|
-5.97
x
|
-37.8
x
|
-28.8
x
|
-24.7
x
|
-22.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
26.1
x
|
24.5
x
|
24.7
x
|
19.3
x
|
EV / Revenue
|
-
|
19.8
x
|
19
x
|
19.3
x
|
13.1
x
|
EV / EBITDA
|
-5.81
x
|
-24.8
x
|
-31.7
x
|
-19
x
|
-15.5
x
|
EV / FCF
|
-10.9
x
|
11.7
x
|
-30.1
x
|
-24.1
x
|
-29.5
x
|
FCF Yield
|
-9.2%
|
8.54%
|
-3.32%
|
-4.15%
|
-3.39%
|
Price to Book
|
-
|
5.98
x
|
4.16
x
|
3.91
x
|
3.51
x
|
Nbr of stocks (in thousands)
|
43,854
|
51,929
|
53,503
|
-
|
-
|
Reference price
2 |
30.98
|
55.50
|
50.78
|
50.78
|
50.78
|
Announcement Date
|
3/29/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
110.3
|
111
|
110
|
140.7
|
EBITDA
1 |
-
|
-63.98
|
-189.9
|
-87.84
|
-66.73
|
-111.9
|
-119.6
|
EBIT
1 |
-
|
-65.02
|
-191.3
|
-89.88
|
-106.6
|
-152.9
|
-151.4
|
Operating Margin
|
-
|
-
|
-
|
-81.47%
|
-95.96%
|
-139.05%
|
-107.63%
|
Earnings before Tax (EBT)
1 |
-32.1
|
-
|
-188.7
|
-70.03
|
-94.52
|
-140.9
|
-134.1
|
Net income
1 |
-32.1
|
-64.97
|
-188.7
|
-70.69
|
-91.8
|
-127.6
|
-127.3
|
Net margin
|
-
|
-
|
-
|
-64.08%
|
-82.67%
|
-115.98%
|
-90.5%
|
EPS
2 |
-
|
-145.6
|
-5.190
|
-1.470
|
-1.764
|
-2.053
|
-2.230
|
Free Cash Flow
1 |
-
|
-
|
-101.6
|
186.1
|
-70.16
|
-88.25
|
-62.6
|
FCF margin
|
-
|
-
|
-
|
168.73%
|
-63.18%
|
-80.24%
|
-44.49%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
1/14/22
|
3/24/22
|
3/29/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
17.91
|
14.3
|
14.96
|
63.15
|
39.26
|
21.54
|
22.55
|
20.36
|
15.09
|
15.09
|
EBITDA
1 |
-
|
-
|
-32.46
|
-93.54
|
-39.59
|
-30.02
|
-29.06
|
-44.42
|
15.72
|
-
|
-15.49
|
-15.15
|
-14.81
|
-
|
-
|
EBIT
1 |
-20.7
|
-32.44
|
-32.61
|
-93.88
|
-40
|
-30.46
|
-29.56
|
-44.86
|
15
|
-15.81
|
-32.68
|
-35.01
|
-36.21
|
-45.7
|
-46.63
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-170.04%
|
-206.68%
|
-299.94%
|
23.75%
|
-40.27%
|
-151.71%
|
-155.27%
|
-177.83%
|
-302.82%
|
-309.01%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-32.09
|
-92.87
|
-38.99
|
-27.02
|
-24.14
|
-39.34
|
20.47
|
-7.198
|
-28.18
|
-30.16
|
-33.7
|
-42.03
|
-42.97
|
Net income
1 |
-20.67
|
-32.38
|
-32.09
|
-92.87
|
-38.99
|
-27.34
|
-23.85
|
-39.34
|
19.84
|
-7.198
|
-28.2
|
-30.18
|
-33.74
|
-42.03
|
-42.97
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-152.66%
|
-166.79%
|
-262.99%
|
31.42%
|
-18.34%
|
-130.91%
|
-133.87%
|
-165.7%
|
-278.53%
|
-284.71%
|
EPS
2 |
-39.85
|
-1.560
|
-0.8800
|
-2.120
|
-0.7600
|
-0.5800
|
-0.5000
|
-0.8100
|
0.4200
|
-0.1400
|
-0.5394
|
-0.5902
|
-0.6291
|
-0.7150
|
-0.7150
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/24/22
|
5/12/22
|
8/15/22
|
11/14/22
|
3/29/23
|
5/8/23
|
8/14/23
|
11/13/23
|
2/28/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
255
|
702
|
603
|
592
|
869
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-102
|
186
|
-70.2
|
-88.3
|
-62.6
|
ROE (net income / shareholders' equity)
|
-
|
-80%
|
-452%
|
-20.5%
|
-3.92%
|
-10.1%
|
-13.3%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
9.280
|
12.20
|
13.00
|
14.50
|
Cash Flow per Share
2 |
-
|
-122.0
|
-2.730
|
4.320
|
-0.7900
|
1.730
|
-
|
Capex
1 |
-
|
5.78
|
2.28
|
21.4
|
9.84
|
10.4
|
14
|
Capex / Sales
|
-
|
-
|
-
|
19.42%
|
8.86%
|
9.43%
|
9.94%
|
Announcement Date
|
1/14/22
|
3/24/22
|
3/29/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
50.78
USD Average target price
79.93
USD Spread / Average Target +57.41% Consensus |
1st Jan change
|
Capi.
|
---|
| -8.50% | 2.72B | | +51.85% | 57.87B | | +41.42% | 40.25B | | -5.25% | 39.94B | | -5.16% | 28.54B | | +12.79% | 26.4B | | -20.18% | 19.33B | | +30.88% | 12.4B | | +0.61% | 12.23B | | +25.06% | 12.2B |
Other Biotechnology & Medical Research
|